GSK2398852, now known as Dezamizumab, represents a novel monoclonal protein currently under medical assessment for its ability to inhibit the enzyme CD22, a vital controller of more info B-cell operation. This treatment approach holds significant hope for alleviating autoimmune diseases, particularl